Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 6-7
Submit an article Journal homepage
2,061
Views
96
CrossRef citations to date
0
Altmetric
Original Article

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

Carl ErikssonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Jan MarsalImmunology Section, Lund University, Lund, Sweden; ;Department of Gastroenterology, Skåne University Hospital, Lund, Sweden; View further author information
,
Daniel BergemalmDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Lina VigrenDepartment of Internal Medicine, Ystad Hospital, Ystad, Sweden; View further author information
,
Jan BjörkDepartment of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet, Solna, Stockholm, Sweden; View further author information
,
Michael EberhardsonDepartment of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet, Solna, Stockholm, Sweden; View further author information
,
Pontus KarlingDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; View further author information
,
Charlotte SödermanDepartment of Internal Medicine, St Göran Hospital, Stockholm, Sweden; View further author information
, The SWIBREG Vedolizumab Study Group,
Pär MyrelidDepartment of Clinical and Experimental Medicine, Linköping University and Department of Surgery, Linköping University Hospital, Linköping, Sweden; View further author information
,
Yang CaoDepartment of Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden; ;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; View further author information
,
Daniel SjöbergCenter for Clinical Research Dalarna, Uppsala University, Falun, Sweden; View further author information
,
Mari ThörnDepartment of Medical Sciences, Section of Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden; View further author information
,
Per KarlénDepartment of Internal Medicine, Danderyd Hospital, Stockholm, Sweden; View further author information
,
Erik HertervigDepartment of Gastroenterology, Skåne University Hospital, Lund, Sweden; View further author information
,
Hans StridDepartment of Internal Medicine, Södra Älvsborgs Sjukhus, Borås, Sweden; View further author information
,
Jonas F. LudvigssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ;Department of Pediatrics, Örebro University Hospital, Örebro, SwedenView further author information
,
Sven AlmerDepartment of Medicine, Center for Digestive Diseases, Karolinska University Hospital, Karolinska Institutet, Solna, Stockholm, Sweden; View further author information
&
Jonas HalfvarsonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Correspondence[email protected]
View further author information
 show all
Pages 722-729 | Received 10 Jan 2017, Accepted 07 Mar 2017, Published online: 31 Mar 2017

Citations (96)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Carl Eriksson, Isabella Visuri, Lina Vigren, Linda Nilsson, Anders Kärnell, Henrik Hjortswang, Daniel Bergemalm, Sven Almer, Erik Hertervig, Per Karlén, Hans Strid & Jonas Halfvarson. (2021) Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology 56:11, pages 1304-1311.
Read now
Ciaran Judge, Neasa McGettigan, Timothy Ryan, Karl Hazel, Pamla Singh, Vikrant Parihar, Roisin Stack, Anthony O’Connor, Cara Dunne, Garret Cullen, Laurence Egan, Gavin Harewood, Finbar MacCarthy, Susan McKiernan, Hugh Mulcahy, Frank Murray, Stephen Patchett, Juliette Sheridan, Danny Cheriyan, Richard Farrell, John Keohane, Orlaith Kelly, Deirdre McNamara, Barbara Ryan, Colm O’Morain, Subhasish Sengupta, Aoibhlinn O’Toole, Martin Buckley, Jane McCarthy, Glen Doherty, David Kevans & Eoin Slattery. (2020) Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 55:7, pages 786-794.
Read now
Renáta Bor, Anna Fábián, Mária Matuz, Zoltán Szepes, Klaudia Farkas, Pál Miheller, Tamás Szamosi, Áron Vincze, Mariann Rutka, Kata Szántó, Anita Bálint, Ferenc Nagy, Ágnes Milassin, Tibor Tóth, Ferenc Zsigmond, Judit Bajor, Katalin Müllner, Lilla Lakner, Mária Papp, Ágnes Salamon, Gábor Horváth, Krisztina Sarang, Eszter Schäfer, Patrícia Sarlós, Károly Palatka & Tamás Molnár. (2020) Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 20:2, pages 205-213.
Read now
Robert Battat, Parambir S. Dulai, Vipul Jairath & Niels Vande Casteele. (2019) A product review of vedolizumab in inflammatory bowel disease. Human Vaccines & Immunotherapeutics 15:10, pages 2482-2490.
Read now
Jonas F. Ludvigsson, Marie Andersson, Jonas Bengtsson, Michael Eberhardson, Ulrika L. Fagerberg, Olof Grip, Jonas Halfvarson, Henrik Hjortswang, Susanna Jäghult, Pontus Karling, Caroline Nordenvall, Ola Olén, Malin Olsson, Martin Rejler, Hans Strid & Pär Myrelid. (2019) Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register. Scandinavian Journal of Gastroenterology 54:9, pages 1089-1101.
Read now
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath & Brian Gordon Feagan. (2019) Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?. Expert Review of Gastroenterology & Hepatology 13:4, pages 319-330.
Read now
Davide Giuseppe Ribaldone, Rinaldo Pellicano, Marta Vernero, Gian Paolo Caviglia, Giorgio Maria Saracco, Mario Morino & Marco Astegiano. (2019) Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scandinavian Journal of Gastroenterology 54:4, pages 407-413.
Read now
Lydia C. T. Buer, Bjørn A. Moum, Milada Cvancarova, David J. Warren, Nils Bolstad, Asle W. Medhus & Marte L. Høivik. (2019) Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort. Scandinavian Journal of Gastroenterology 54:1, pages 41-48.
Read now
Sine Buhl, Märta Kristina Borghede, Jørn Brynskov, Casper Steenholdt, Maria Rasmussen & Mark Andrew Ainsworth. (2018) Outcome of continued infliximab therapy in Crohn’s disease patients with response but without remission after one year of infliximab – a retrospective cohort study. Scandinavian Journal of Gastroenterology 53:8, pages 930-937.
Read now
Bani Ahluwalia, Luiza Moraes, Maria K. Magnusson & Lena Öhman. (2018) Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scandinavian Journal of Gastroenterology 53:4, pages 379-389.
Read now
Tero Ylisaukko-oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen & Taina Sipponen. (2018) High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scandinavian Journal of Gastroenterology 53:2, pages 158-167.
Read now

Articles from other publishers (85)

N. Lamichhane, N. Melas, V. Bergqvist, N.-P. Ekholm, O. Olén, J. F. Ludvigsson, H. Hjortswang, J. Marsal, C. Eriksson & J. Halfvarson. (2024) Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences.
Crossref
Tarun Chhibba, Emily C.L. Wong, Walter Reinisch, Laura Targownik & Neeraj Narula. (2024) Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. European Journal of Gastroenterology & Hepatology.
Crossref
Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar & Gregor Novak. (2024) Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina 60:2, pages 296.
Crossref
E. S. Peda, B. A. Nanaeva, O. V. Knyazev, T. L. Alexandrov & T. A. Baranova. (2024) Long-term efficacy of vedolizumab therapy in patients with Crohn’s disease. Experimental and Clinical Gastroenterology:9, pages 34-41.
Crossref
Laura E Targownik, Natasha Bollegala, Vivian W Huang, Joseph W Windsor, M Ellen Kuenzig, Eric I Benchimol, Gilaad G Kaplan, Sanjay K Murthy, Alain Bitton, Charles N Bernstein, Jennifer L Jones, Kate Lee, Juan-Nicolás Peña-Sánchez, Noelle Rohatinsky, Sara Ghandeharian, Tal Davis, Jake Weinstein, James H B Im, Nazanin Jannati, Rabia Khan, Priscilla Matthews, Tyrel Jones May, Sahar Tabatabavakili, Rohit Jogendran, Elias Hazan, Mira Browne, Saketh Meka, Sonya Vukovic, Manisha Jogendran, Malini Hu, Jessica Amankwah Osei, Grace Y Wang, Tasbeen Akhtar Sheekha, Ghaida Dahlwi, Quinn Goddard, Julia Gorospe, Cyanne Nisbett, Shira Gertsman, James Sousa, Taylor Morganstein, Taylor Stocks, Ann Weber & Cynthia H Seow. (2023) The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology 6:Supplement_2, pages S55-S63.
Crossref
Fabio Salvatore Macaluso, Marco Ventimiglia & Ambrogio Orlando. (2023) Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. Journal of Crohn's and Colitis 17:8, pages 1217-1227.
Crossref
Samuel Hui, Vassiliki Sinopoulou, Morris Gordon, Ghazaleh Aali, Anuj Krishna, Nik Sheng Ding & Ray K Boyapati. (2023) Vedolizumab for induction and maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Teresa Hof, Robert Thimme & Peter Hasselblatt. (2023) Diversitätsfaktoren in der Gastroenterologie. DMW - Deutsche Medizinische Wochenschrift 148:09, pages 519-527.
Crossref
Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan Vavricka, Katja Tepes, Daniela Pugliese, Edoardo Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin & Uri Kopylov. (2023) Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine 12:7, pages 2503.
Crossref
Piotr Eder, Maria Kłopocka, Halina Cichoż-Lach, Renata Talar-Wojnarowska, Maria Kopertowska-Majchrzak, Agata Michalak, Rafał Filip, Katarzyna Waszak, Kamila Stawczyk-Eder, Maria Janiak, Krzysztof Skrobot, Ariel Liebert, Hubert Zatorski, Anna Solarska-Półchłopek, Michał Krogulecki, Anna Pękała, Elżbieta Poniewierka, Izabela Smoła, Aleksandra Kaczka, Krzysztof Wojciechowski, Szymon Drygała & Edyta Zagórowicz. (2023) Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study. Therapeutic Advances in Gastroenterology 16, pages 175628482311512.
Crossref
Magdalena Wlazło, Monika Meglicka, Anna Wiernicka, Marcin Osiecki & Jarosław Kierkuś. (2022) Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study. Children 10:1, pages 11.
Crossref
Leiqi Xu, Gang Huang, Yingzi Cong, Yanbo Yu & Yanqing Li. (2022) Sex-related Differences in Inflammatory Bowel Diseases: The Potential Role of Sex Hormones. Inflammatory Bowel Diseases 28:11, pages 1766-1775.
Crossref
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona van Schaik, Jeroen Maljaars, Krisztina Gecse, Cyriel Ponsioen, Joep Grootjans, Jurij Hanzel, Greetje Tack, Jeroen Jansen, Frank Hoentjen, Nanne de Boer, Sander van der Marel, Gerard Dijkstra, Bas Oldenburg, Mark Löwenberg, Andrea van der Meulen & Geert D′Haens. (2022) Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 56:6, pages 1044-1054.
Crossref
Emily M. Heath, Richard B. Kim & Aze Wilson. (2021) A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease. Digestive Diseases and Sciences 67:9, pages 4287-4294.
Crossref
Joel Thunberg, Olle Björkqvist, Charlotte R. H. Hedin, Anders Forss, Charlotte Söderman, Daniel Bergemalm, Ola Olén, Henrik Hjortswang, Hans Strid, Jonas F. Ludvigsson, Carl Eriksson & Jonas Halfvarson. (2022) Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterology Journal 10:7, pages 631-639.
Crossref
Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman & Jan Marsal. (2022) Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 55:11, pages 1389-1401.
Crossref
Magdalena Wlazło & Jarosław Kierkuś. (2022) Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature. Journal of Clinical Medicine 11:7, pages 2004.
Crossref
Giorgos Bamias, Georgios Kokkotis, Michalis Gizis, Christina Kapizioni, Konstantinos Karmiris, Evgenia Koureta, Nikolaos Kyriakos, Georgios Leonidakis, Konstantinos Makris, Panagiotis Markopoulos, Georgios Michalopoulos, Spyridon Michopoulos, Ioannis Papaconstantinou, Dimitrios Polymeros, Spyros I. Siakavellas, Konstantinos Triantafyllou, Eftychia Tsironi, Emmanouela Tsoukali, Maria Tzouvala, Nikos Viazis, Vassileios Xourafas, Eirini Zacharopoulou, Evanthia Zampeli, Konstantinos Zografos, George Papatheodoridis & Gerasimos Mantzaris. (2021) Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Digestive Diseases and Sciences 67:3, pages 1007-1017.
Crossref
Ayça Gökçen DEĞİRMENCİ SALTÜRK. (2022) İnflamatuvar Barsak Hastalarında Vedolizumab Deneyimi: Tek Merkez Verileri. Akademik Gastroenteroloji Dergisi 20:3, pages 169-173.
Crossref
Andrea Cassinotti, Alberto Batticciotto, Marco Parravicini, Maurizio Lombardo, Paolo Radice, Claudio Camillo Cortelezzi, Simone Segato, Federico Zanzi, Antonella Cappelli & Sergio Segato. (2022) Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeutic Advances in Gastroenterology 15, pages 175628482210858.
Crossref
Yonghoon Choi & Nayoung Kim. 2022. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases 281 299 .
Jeongseok Kim, Hyuk Yoon, Nayoung Kim, Kang-Moon Lee, Sung-Ae Jung, Chang Hwan Choi, Eun Soo Kim, Yunho Jung, Chang Soo Eun, Tae Oh Kim, Sang-Bum Kang, You Sun Kim, Geom-Seog Seo, Chang Kyun Lee, Jong Pil Im, Soo Jung Park, Dong Il Park & Byong Duk Ye. (2021) Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflammatory Bowel Diseases 27:12, pages 1931-1941.
Crossref
Brian Bressler, Andres Yarur, Mark S Silverberg, Marielle Bassel, Emanuelle Bellaguarda, Chris Fourment, Anthie Gatopoulou, Pantelis Karatzas, Uri Kopylov, George Michalopoulos, Spyridon Michopoulos, Udayakumar Navaneethan, David T Rubin, Jesse Siffledeen, Andrew Singh, Konstantinos Soufleris, Dara Stein, Dirk Demuth & Gerassimos J Mantzaris. (2021) Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. Journal of Crohn's and Colitis 15:10, pages 1694-1706.
Crossref
Ann-Lorie Gagnon, William Beauchesne, Laurence Tessier, Charles David, Djamal Berbiche, Alexandre Lavoie, Alban Michaud-Herbst & Karine Tremblay. (2021) Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center. Crohn's & Colitis 360 3:4.
Crossref
Cath Stansfield. (2021) Vedolizumab (Entyvio) in Crohn's disease. Gastrointestinal Nursing 19:6, pages 20-26.
Crossref
Temara M Hajjat, Maua Mosha, Kaitlin G Whaley, Michael J Rosen, Carmine Suppa, James Markowitz, Lauren Dufour, Cary Sauer, Monica Shukla-Udawatta, Brendan Boyle, Meghan Gibson, Jason Shapiro, Derica Sams, Francisco Sylvester, Gabriele Hunter, Maria E Perez & Jeffrey S Hyams. (2021) Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study. Crohn's & Colitis 360 3:3.
Crossref
Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison Jess, Pei-Shun Li, Karen Kroeker, Brendan Halloran, Remo Panaccione, Laurent Peyrin-Biroulet, Christopher Ma & Ashwin N. Ananthakrishnan. (2021) Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology 19:7, pages 1366-1376.e2.
Crossref
Giuseppe Privitera, Daniela Pugliese, Sara Onali, Valentina Petito, Franco Scaldaferri, Antonio Gasbarrini, Silvio Danese & Alessandro Armuzzi. (2021) Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmunity Reviews 20:6, pages 102832.
Crossref
Seong-Eun Kim. (2021) How Should We Do Different Approach to Treat Inflammatory Bowel Disease by Gender Difference?. The Korean Journal of Gastroenterology 77:5, pages 241-247.
Crossref
Clara Yzet, Momar Diouf, Siddarth Singh, Franck Brazier, Justine Turpin, Eric Nguyen-Khac, Jonathan Meynier & Mathurin Fumery. (2021) No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis. Clinical Gastroenterology and Hepatology 19:4, pages 668-679.e8.
Crossref
Qi-Wen Jin & Xiao-Di Wang. (2021) Progress in research of vedolizumab in treatment of inflammatory bowel disease. World Chinese Journal of Digestology 29:5, pages 248-255.
Crossref
Sara Rundquist, Michael C. Sachs, Carl Eriksson, Ola Olén, Scott Montgomery & Jonas Halfvarson. (2020) Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary Pharmacology & Therapeutics 53:4, pages 471-483.
Crossref
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała & Edyta Zagórowicz. (2021) Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology 14, pages 175628482110364.
Crossref
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang & Jonas Halfvarson. (2021) Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology 14, pages 175628482110233.
Crossref
Prasanta Debnath & Pravin M. Rathi. (2021) Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflammatory Intestinal Diseases 6:1, pages 1-17.
Crossref
Wendy A. Goodman, Ian P. Erkkila & Theresa T. Pizarro. (2020) Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 17:12, pages 740-754.
Crossref
Fabio Salvatore Macaluso, Walter Fries, Sara Renna, Anna Viola, Marco Muscianisi, Maria Cappello, Laura Guida, Sebastiano Siringo, Salvatore Camilleri, Serena Garufi, Antonino Carlo Privitera, Nunzio Belluardo, Emiliano Giangreco, Carmelo Bertolami, Roberto Vassallo, Giulia Rizzuto, Rosalba Orlando, Marco Ventimiglia & Ambrogio Orlando. (2020) Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study. United European Gastroenterology Journal 8:9, pages 1045-1055.
Crossref
Tristan Townsend, Violeta Razanskaite, Susanna Dodd, Daniel Storey, Stephanie Michail, James Morgan, Michael Davies, Douglas Penman, Christopher Watters, Mira Swaminathan, Joseph Sabine, Adam Chapman, Philip J Smith, Paul K. Flanagan, Ian Reilly, Keith Bodger & Sreedhar Subramanian. (2020) Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease. Alimentary Pharmacology & Therapeutics 52:8, pages 1341-1352.
Crossref
Marina Coletta, Moira Paroni, Maria Francesca Alvisi, Matilde De Luca, Eliana Rulli, Stefano Mazza, Federica Facciotti, Georgia Lattanzi, Francesco Strati, Sergio Abrignani, Massimo Claudio Fantini, Maurizio Vecchi, Jens Geginat & Flavio Caprioli. (2020) Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. Journal of Crohn's and Colitis 14:9, pages 1190-1201.
Crossref
Samba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, Daniel Cheng, Jakob Begun, Charlotte Keung, Daniel Van Langenberg, Lena Thin, Tamara Mogilevski, Peter De Cruz, Graham Radford-Smith, Emma Flanagan, Sally Bell, Soleiman Kashkooli, Miles Sparrow, Simon Ghaly, Peter Bampton, Elise Sawyer, Susan Connor, Quart-ul-ain Rizvi, Jane M Andrews, Gillian Mahy, Paola Chivers, Simon Travis & Ian Craig Lawrance. (2020) Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World Journal of Gastroenterology 26:30, pages 4428-4441.
Crossref
Patrizio Scarozza, Elena De Cristofaro, Ludovica Scucchi, Irene Rocchetti, Irene Marafini, Benedetto Neri, Silvia Salvatori, Livia Biancone, Emma Calabrese & Giovanni Monteleone. (2020) Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine 9:7, pages 2126.
Crossref
Lorenzo Bertani, Laura Baglietto, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Eleonora Albano, Linda Ceccarelli, Maria Gloria Mumolo, Carolina Pellegrini, Ersilia Lucenteforte, Nicola de Bortoli, Massimo Bellini, Santino Marchi, Corrado Blandizzi & Francesco Costa. (2020) Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. British Journal of Clinical Pharmacology 86:7, pages 1296-1305.
Crossref
Jason Reinglas, Lorant Gonczi, Christine Verdon, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest Seidman, Alain Bitton & Peter L. Lakatos. (2019) Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Digestive Diseases and Sciences 65:7, pages 2046-2053.
Crossref
Mirabella Zhao & Johan Burisch. (2020) The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn’s Disease. Journal of Crohn's and Colitis 14:5, pages 573-574.
Crossref
Lorenzo Bertani, Gian Paolo Caviglia, Luca Antonioli, Rinaldo Pellicano, Sharmila Fagoonee, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Corrado Blandizzi, Francesco Costa & Davide Giuseppe Ribaldone. (2020) Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine 9:5, pages 1323.
Crossref
Hadrien Alric, Aurélien Amiot, Julien Kirchgesner, Xavier Tréton, Matthieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel & Antoine Meyer. (2020) The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor. Alimentary Pharmacology & Therapeutics 51:10, pages 948-957.
Crossref
Vince B.C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, Bas Oldenburg, Nanne K. de Boer, Mark Löwenberg, Nidhi Srivastava, Alexander G.L. Bodelier, Rachel L. West, Jeroen M. Jansen, Annemarie C. de Vries, Jeoffrey J.L. Haans, Dirk J. de Jong, Marie J. Pierik & Frank Hoentjen. (2019) Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. Clinical Pharmacology & Therapeutics 107:5, pages 1189-1199.
Crossref
Peng Chen, Gaoshi Zhou, Jingxia Lin, Li Li, Zhirong Zeng, Minhu Chen & Shenghong Zhang. (2020) Serum Biomarkers for Inflammatory Bowel Disease. Frontiers in Medicine 7.
Crossref
Patrizio Scarozza, Irene Marafini, Federica Laudisi, Edoardo Troncone, Heike Schmitt, Marco Vincenzo Lenti, Stefania Costa, Irene Rocchetti, Elena De Cristofaro, Silvia Salvatori, Ludovica Frezzati, Antonio Di Sabatino, Raja Atreya, Markus F. Neurath, Emma Calabrese & Giovanni Monteleone. (2020) Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine 9:2, pages 385.
Crossref
Fabiana Zingone, Brigida Barberio, Federico Compostella, Giulia Girardin, Renata D’Incà, Carla Marinelli, Ilaria Marsilio, Greta Lorenzon & Edoardo Vincenzo Savarino. (2020) Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario. Therapeutic Advances in Gastroenterology 13, pages 175628482093653.
Crossref
Sheila D. Rustgi, Maia Kayal & Shailja C. Shah. (2020) Sex-based differences in inflammatory bowel diseases: a review. Therapeutic Advances in Gastroenterology 13, pages 175628482091504.
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Bharati Kochar, Yue Jiang, Aaron Winn, Edward L Barnes, Christopher F Martin, Millie D Long & Michael D Kappelman. (2019) The Early Experience With Vedolizumab in the United States. Crohn's & Colitis 360 1:3.
Crossref
N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, A J M Watson, D A Watts, G R Jones & C W Lees. (2019) Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Journal of Crohn's and Colitis 13:9, pages 1111-1120.
Crossref
Kellyn Moran, Kyle Null, Zhongwen Huang, Trevor Lissoos & Sunanda Kane. (2019) Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Advances in Therapy 36:9, pages 2260-2272.
Crossref
Rebecca Davis, Paula McParland, Susanna Dodd, Daniel Storey, Chris Probert, Paul Collins, Thomas Skouras, Alan Steel, Edmund Derbyshire, Martyn Dibb & Sreedhar Subramanian. (2019) Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. European Journal of Gastroenterology & Hepatology 31:6, pages 661-667.
Crossref
Christopher R. Lindholm & Corey A. Siegel. (2019) Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. Current Pharmaceutical Design 25:1, pages 64-68.
Crossref
Gabriele Dragoni, Siro Bagnoli, Marco Le Grazie, Claudia Campani, Francesca Rogai, Natalia Manetti, Carolina Bensi, Giuseppe Macrì, Andrea Galli & Monica Milla. (2019) Long‐term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real‐life experience from a tertiary referral center. Journal of Digestive Diseases 20:5, pages 235-242.
Crossref
Robert Battat, Christopher Ma, Vipul Jairath, Reena Khanna & Brian G. Feagan. (2019) Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Safety 42:5, pages 617-632.
Crossref
Claire Liefferinckx, Charlotte Minsart, Anneline Cremer, Leila Amininejad, Vjola Tafciu, Eric Quertinmont, Sophie Tops, Jacques Devière, Ann Gils, André van Gossum & Denis Franchimont. (2019) Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. European Journal of Gastroenterology & Hepatology 31:4, pages 478-485.
Crossref
Tero Ylisaukko-oja, Saku Torvinen, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen & Taina Sipponen. (2019) Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice. Biologicals 58, pages 50-56.
Crossref
Gauthier Pellet, Carmen Stefanescu, Franck Carbonnel, Laurent Peyrin-Biroulet, Xavier Roblin, Christophe Allimant, Maria Nachury, Stephane Nancey, Jerome Filippi, Romain Altwegg, Hedia Brixi, Ginette Fotsing, Laure de Rosamel, Sarah Shili & David Laharie. (2019) Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clinical Gastroenterology and Hepatology 17:3, pages 494-501.
Crossref
Christopher Ma, Robert Battat, Reena Khanna, Claire E. Parker, Brian G. Feagan & Vipul Jairath. (2019) What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. Best Practice & Research Clinical Gastroenterology 38-39, pages 101602.
Crossref
Philipp Schreiner, Markus F. Neurath, Siew C. Ng, Emad M. El-Omar, Ala I. Sharara, Taku Kobayashi, Tadakazu Hisamatsu, Toshifumi Hibi & Gerhard Rogler. (2019) Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases 4:3, pages 79-96.
Crossref
Uri Kopylov, Irit Avni-Biron, Yulia Ron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Doron Schwartz, Eran Zittan, Michal Openhaim, Henit Yanai, Nitsan Maharshak, Ariella Bar Gil Shitrit, Timna Naftali, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin & Iris Dotan. (2019) Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience. Digestive and Liver Disease 51:1, pages 68-74.
Crossref
Marco Vincenzo Lenti, Scott Levison, Elena Eliadou, Robert Willert, Karen Kemp, Anna Carter, Catherine Stansfield, Arash Assadsangabi, Salil Singh, Ben Crooks, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Sreedhar Subramanian, Chris Probert, Daniel Storey, Belle Gregg, Paul Smith, Eleanor Liu, Jimmy K. Limdi, Alex Johnston, Peter John Hamlin & Christian P. Selinger. (2018) A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Digestive and Liver Disease 50:12, pages 1299-1304.
Crossref
Marisa Iborra, Belén Beltrán, Nuria Maroto, Pablo Navarro-Cortés, Maia Boscá-Watts, Isabel Ferrer-Bradley, Natalia García-Morales, Esteban Sáez-González, Joaquín Hinojosa, Miguel Mínguez & Pilar Nos. (2018) Vedolizumab, una opción en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biológicos. Gastroenterología y Hepatología 41:9, pages 535-543.
Crossref
Marisa Iborra, Belén Beltrán, Nuria Maroto, Pablo Navarro-Cortés, Maia Boscá-Watts, Isabel Ferrer-Bradley, Natalia García-Morales, Esteban Sáez-González, Joaquín Hinojosa, Miguel Mínguez & Pilar Nos. (2018) Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Gastroenterología y Hepatología (English Edition) 41:9, pages 535-543.
Crossref
Christopher M. Johnson & Themistocles Dassopoulos. (2018) Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Current Gastroenterology Reports 20:11.
Crossref
Uri Kopylov, Bram Verstockt, Luc Biedermann, Shaji Sebastian, Daniela Pugliese, Elena Sonnenberg, Peter Steinhagen, Naila Arebi, Yulia Ron, Torsten Kucharzik, Xavier Roblin, Bella Ungar, Ariella Bar-Gil Shitrit, Sandro Ardizzone, Pauliina Molander, Marina Coletta, Laurent Peyrin-Biroulet, Peter Bossuyt, Irit Avni-Biron, Emmanouela Tsoukali, Mariangela Allocca, Konstantinos Katsanos, Tim Raine, Taina Sipponen, Gionata Fiorino, Shomron Ben-Horin, Rami Eliakim, Alessandro Armuzzi, Britta Siegmund, Daniel C Baumgart, Nikolaos Kamperidis, Nitsan Maharshak, Christian Maaser, Gerassimos Mantzaris, Henit Yanai, Dimitrious K Christodoulou, Iris Dotan & Marc Ferrante. (2018) Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases 24:11, pages 2442-2451.
Crossref
A. O. Golovenko & O. V. Golovenko. (2018) Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?. Medical Council:14, pages 44-49.
Crossref
María Chaparro, Ana Garre, Elena Ricart, Marisa Iborra, Francisco Mesonero, Isabel Vera, Sabino Riestra, Valle García‐Sánchez, M. Luisa De Castro, Albert Martin‐Cardona, Xavier Aldeguer, Miguel Mínguez, Manuel Barreiro de‐Acosta, Montserrat Rivero, Fernando Muñoz, Montserrat Andreu, Ana Bargalló, Carlos González‐Muñoza, Jose L. Pérez Calle, Mariana Fe García‐Sepulcre, Fernando Bermejo, Jose Maria Huguet, José L. Cabriada, Ana Gutiérrez, Míriam Mañosa, Albert Villoria, Ana Y. Carbajo, Rufo Lorente, Santiago García‐López, Marta Piqueras, Esther Hinojosa, Clàudia Arajol, Beatriz Sicilia, Ana Macho Conesa, Empar Sainz, Pedro Almela, Jordina Llaó, Oscar Roncero, Patricia Camo, Carlos Taxonera, Manuel Van Domselaar, Ramón Pajares, Jesús Legido, Rosa Madrigal, Alfredo J. Lucendo, Guillermo Alcaín, Eugeni Doménech & Javier P. Gisbert. (2018) Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Alimentary Pharmacology & Therapeutics 48:8, pages 839-851.
Crossref
Hang Hock Shim, Pak Wo Chan, Sai Wei Chuah, Brian J Schwender, San Choon Kong & Khoon Lin Ling. (2018) A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2:5, pages 223-234.
Crossref
Neeraj Narula, Farhad Peerani, Joseph Meserve, Gursimran Kochhar, Khadija Chaudrey, Justin Hartke, Prianka Chilukuri, Jenna Koliani-Pace, Adam Winters, Leah Katta, Eugenia Shmidt, Robert Hirten, David Faleck, Malav P. Parikh, Diana Whitehead, Brigid S. Boland, Siddharth Singh, Sashidhar Varma Sagi, Monika Fischer, Shannon Chang, Morris Barocas, Michelle Luo, Karen Lasch, Matthew Bohm, Dana Lukin, Keith Sultan, Arun Swaminath, David Hudesman, Nitin Gupta, Bo Shen, Sunanda Kane, Edward V. Loftus, Corey A. Siegel, Bruce E. Sands, Jean-Frederic Colombel, William J. Sandborn & Parambir S. Dulai. (2018) Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology 113:9, pages 1345.
Crossref
Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Dario Pluchino, Maria Cappello, Gaetano Cristian Morreale, Sebastiano Siringo, Antonino Carlo Privitera, Concetta Ferracane, Nunzio Belluardo, Nadia Alberghina, Marco Ventimiglia, Giulia Rizzuto, Sara Renna, Mario Cottone & Ambrogio Orlando. (2018) The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Digestive and Liver Disease 50:7, pages 675-681.
Crossref
Maria Lia Scribano. (2018) Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World Journal of Gastroenterology 24:23, pages 2457-2467.
Crossref
Robert E. Carroll. (2018) Endoscopic Follow-up of Intestinal Transplant Recipients. Gastroenterology Clinics of North America 47:2, pages 381-391.
Crossref
Lydia C T Buer, Marte L Høivik, David J Warren, Asle W Medhus & Bjørn A Moum. (2018) Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflammatory Bowel Diseases 24:5, pages 997-1004.
Crossref
Martine De Vos, Barbara Dhooghe, Severine Vermeire, Edouard Louis, Fazia Mana, Ann Elewaut, Peter Bossuyt, Filip Baert, Catherine Reenaers, Marc Van Gossum, Elisabeth Macken, Marc Ferrante, Pieter Hindryckx, Olivier Dewit, Tom Holvoet & Denis Franchimont. (2017) Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal 6:3, pages 439-445.
Crossref
A. Barré, J.‐F. Colombel & R. Ungaro. (2018) Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 47:7, pages 896-905.
Crossref
Steven Bots, Krisztina Gecse, Murray Barclay & Geert D’Haens. (2018) Combination Immunosuppression in IBD. Inflammatory Bowel Diseases 24:3, pages 539-545.
Crossref
Marjorie C. Argollo, Paulo Gustavo Kotze, Antonino Spinelli, Tarcia N.F. Gomes & Silvio Danese. (2018) The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 32-33, pages 79-87.
Crossref
Charlotte Hedin & Jonas Halfvarson. (2018) Should we use vedolizumab as mono or combo therapy in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 32-33, pages 27-34.
Crossref
Tal Engel, Bella Ungar, Diana E Yung, Shomron Ben-Horin, Rami Eliakim & Uri Kopylov. (2018) Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. Journal of Crohn's and Colitis 12:2, pages 245-257.
Crossref
Marcel Vetter & Markus F. Neurath. (2017) Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therapeutic Advances in Gastroenterology 10:10, pages 773-790.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.